Non-alcoholic Fatty Liver Disease
"Non-alcoholic Fatty Liver Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Descriptor ID |
D065626
|
| MeSH Number(s) |
C06.552.241.519
|
| Concept/Terms |
Non-alcoholic Fatty Liver Disease- Non-alcoholic Fatty Liver Disease
- Non alcoholic Fatty Liver Disease
- NAFLD
- Nonalcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- Fatty Livers, Nonalcoholic
- Liver, Nonalcoholic Fatty
- Livers, Nonalcoholic Fatty
- Nonalcoholic Fatty Liver
- Nonalcoholic Fatty Livers
Nonalcoholic Steatohepatitis- Nonalcoholic Steatohepatitis
- Nonalcoholic Steatohepatitides
- Steatohepatitides, Nonalcoholic
- Steatohepatitis, Nonalcoholic
|
Below are MeSH descriptors whose meaning is more general than "Non-alcoholic Fatty Liver Disease".
Below are MeSH descriptors whose meaning is more specific than "Non-alcoholic Fatty Liver Disease".
This graph shows the total number of publications written about "Non-alcoholic Fatty Liver Disease" by people in this website by year, and whether "Non-alcoholic Fatty Liver Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 9 | 9 |
| 2013 | 1 | 7 | 8 |
| 2014 | 5 | 1 | 6 |
| 2015 | 9 | 0 | 9 |
| 2016 | 10 | 4 | 14 |
| 2017 | 10 | 1 | 11 |
| 2018 | 6 | 3 | 9 |
| 2019 | 10 | 1 | 11 |
| 2020 | 24 | 1 | 25 |
| 2021 | 32 | 2 | 34 |
| 2022 | 31 | 0 | 31 |
| 2023 | 29 | 1 | 30 |
| 2024 | 13 | 4 | 17 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Non-alcoholic Fatty Liver Disease" by people in Profiles.
-
Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017-2023. Aliment Pharmacol Ther. 2025 Mar; 61(5):891-894.
-
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Lancet Gastroenterol Hepatol. 2025 Jan; 10(1):82-94.
-
Ablation of Hepatic Asah1 Gene Disrupts Hepatic Lipid Homeostasis and Promotes Fibrotic Nonalcoholic Steatohepatitis in Mice. Am J Pathol. 2025 Mar; 195(3):542-560.
-
Comparison of deep learning schemes in grading non-alcoholic fatty liver disease using B-mode ultrasound hepatorenal window images with liver biopsy as the gold standard. Phys Med. 2025 Jan; 129:104862.
-
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort. Hepatol Commun. 2024 Nov 01; 8(11).
-
Environmental toxicants modulate disease severity in pediatric metabolic dysfunction-associated steatohepatitis. J Pediatr Gastroenterol Nutr. 2024 Nov; 79(5):943-953.
-
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024 Jul 25; 391(4):371-372.
-
The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer. Int J Mol Sci. 2024 Jun 05; 25(11).
-
Renal impairment is prevalent in pediatric NAFLD/MASLD and associated with disease severity. J Pediatr Gastroenterol Nutr. 2024 Aug; 79(2):238-249.
-
An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.